1. Academic Validation
  2. Discovery and optimization of isoliquiritigenin as a death-associated protein kinase 1 inhibitor

Discovery and optimization of isoliquiritigenin as a death-associated protein kinase 1 inhibitor

  • Eur J Med Chem. 2024 Sep 4:279:116836. doi: 10.1016/j.ejmech.2024.116836.
Takeshi Yokoyama 1 Kotono Hisatomi 2 Saki Oshima 2 Ichiro Tanaka 3 Takuya Okada 2 Naoki Toyooka 2
Affiliations

Affiliations

  • 1 Faculty of Pharmaceutical Sciences, University of Toyama, 2630 Sugitani, Toyama, 930-0914, Japan. Electronic address: tyokoya3@pha.u-toyama.ac.jp.
  • 2 Graduate School of Pharma-Medical Sciences, University of Toyama, 3190 Gofuku, Toyama, 930-8555, Japan.
  • 3 Graduate School of Science and Engineering, Ibaraki University, Nakanarusawa 4-12-1, Hitachi, Ibaraki, 316-8511, Japan.
Abstract

Death-associated protein kinase 1 (DAPK1) is a phosphotransferase in the serine/threonine kinase family. Inhibiting DAPK1 is expected to be beneficial in treating Alzheimer's disease and protecting neuronal cells during cerebral ischemia. In this study, we demonstrated that the natural chalcone isoliquiritigenin inhibits DAPK1 in an ATP-competitive manner, and we synthesized halogen derivatives to amplify the inhibitory effect. Among the compounds tested, the chlorine, bromine, and iodine derivatives exhibited high DAPK1 inhibitory activity and binding affinity. Crystal structure analysis revealed that this improvement is attributable to the halogen atoms fitting well into the hydrophobic pocket formed by I77, L93, and I160. In particular, the chlorine derivative showed a significant enthalpic contribution to the interaction with DAPK1, suggesting its potential as a primary compound for new DAPK1 inhibitors.

Keywords

Death-associated protein kinase 1; Inhibitor; Protein crystallography; isoliquiritigenin.

Figures
Products